AcuCort AB (Spotlight Stock Market: ACUC) today announced that the company’s CEO Jonas Jönmark will participate and present at a number of events arranged by the Swedish Aktiespararna.
The agenda and further details regarding the events, as well as details on accessing the digital events, will be made available on the Aktiespararna’s website. The presentations will be recorded and will be available following the conclusion of the events on AcuCort’s website, at the IR section.
AcuCort to present at the following events:
- September 7, Aktiespararnas Aktiedag in Stockholm
- September 28, Aktiespararnas Aktiedag in Lund
- November 9, Stora Aktiedagen in Gothenburg
- November 29, Stora Aktiedagen in Stockholm.
The presentations will be held in Swedish.
The information was submitted for publication, through the agency of the contact person
below, on August 23, 2021.
For more information, please contact:
Jonas Jönmark, CEO, AcuCort AB
Telephone: + 46 (0)70 365 5400
About AcuCort AB (publ)
AcuCort develops and commercializes ISICORT®, a new fast-dissolving oral film to put on the tongue, based on a well-known cortisone substance – dexamethasone. ISICORT® is a smart product in a new, innovative, patented and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and chemotherapy-induced nausea and vomiting (CINV). A national application was approved by the Swedish Medical Products Agency (MPA) in October 2020. In February 2021, ISICORT® was granted an additional indication – the treatment of COVID-19 patients who need supplemental oxygen treatment. Altogether, this strengthens the company’s assessment that the time to commercialization of ISICORT® may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden. Please visit www.acucort.com.